Technology ID
TAB-2738

Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples

E-Numbers
E-232-1993-0
E-232-1993-1
Lead Inventor
Heneine, Walid (CDC)
Co-Inventors
Folks, Thomas (CDC)
Yamamoto, Shinji
Switzer, William (CDC)
Applications
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
Lead IC
CDC
ICs
CDC
CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of group O infections raised public health concerns about the safety of the blood supply because HIV-1 screening by group M-based serologic tests does not consistently detect group O infection.

The assay is based on the selective inhibition of Amp-RT reactivity of Group M viruses by nevirapine, a non-nucleoside RT inhibitor. Group O viruses can be generically identified by the resistance of their Amp-RT activity to nevirapine. The assay can be used to screening of the blood supply and to rapidly differentiate group M from group O virus.
Commercial Applications
  • Clinical monitoring of individual patient antiretroviral therapy
  • HIV/AIDS public health programs
  • Surveillance of retroviral drug resistance
  • Screening of blood donations
Competitive Advantages
  • Rapid diagnostic which greatly reduces time and labor for improved clinical monitoring of HIV treatment
  • Ready for commercialization
  • Easily adapted to kit format
  • Assists continued usefulness of common antiretroviral therapeutics
  • Useful for high-throughput serum samples screening
Licensing Contact:
Specialist (ALS), Admin. Licensing
nihott@nih.gov